<DOC>
	<DOCNO>NCT01803308</DOCNO>
	<brief_summary>The purpose study compare safety tolerability ascend dos SB 9200 give 14 day subject chronic Hepatitis C infection .</brief_summary>
	<brief_title>A Multiple Ascending Dose Phase I Study SB 9200 Treatment Naïve Adults With Chronic Hepatitis C Infection</brief_title>
	<detailed_description>This First-in-human , Two-stage , Multi-centre study . Part A open-label , single ascend dose study feed fast subject Part B randomize , placebo-controlled multiple ascend dose study . The study design evaluate safety tolerability ascend dos SB 9200 give monotherapy 14 day subject chronic Hepatitis C infection , determine pharmacokinetic pharmacodynamic relationship dose range .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Must provide write informed consent assessment perform . Must willing able comply schedule visit , treatment plan , laboratory test , study procedure . Males females nonchildbearing potential age 18 60 year , inclusive . Must HCV laboratory evidence HCV infection least six month Screening Visit . Must HCV1 ( 1a 1b nonsubtypeable HCV1 ) , HCV2 HCV3 , applicable give cohort . Subjects must plasma HCV RNA &gt; 5 log10 IU/mL ( 100,000 IU/mL ) . Must fibrosis Stage 2 low Ishak Metavir score system equivalent evidence recent ( within two year screen ) liver biopsy ( i.e . moderate fibrosis ) . If recent liver biopsy available , Fibroscan &lt; 8.5 kilopascals screen . Must negative human immunodeficiency virus ( HIV ) Hepatitis B screen test result . Must body mass index ( BMI ) 1832 kg/m2 ( inclusive ) . Must screen laboratory value within reference range outside normal range , clinically significant judged Investigator . ALT aspartate aminotransferase ( AST ) must within 2x upper limit normal . Must consume grapefruit grapefruitrelated citrus fruit juice seven day prior first dose study drug collection final PK blood sample 14 day last dose study drug . Must able communicate site personnel understand instruction . Any previous treatment investigational approved drug drug regimen treatment HCV . Note : SB 9200 exclude criterion , i.e . subject complete Part A study eligible participate Part B study . History hypersensitivity study drug drug similar chemical class . Use nonprescription drug , vitamin dietary supplement within 14 day five halflives ( whichever longer ) prior trial dose medication . Changes prescription medication within 14 day prior first dose study medication ( i.e . stable prescription medication permit whilst study ) . History intercurrent illness ( e.g. , upper respiratory illness fever ) within five day prior first dose study drug . History illicit control substance abuse alcohol abuse within one year Screening Visit ( exception cannabinoids ) . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . Long QT syndrome QTc &gt; 450 msec male &gt; 470 msec female screen baseline . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past five year , regardless whether evidence local recurrence metastasis . Women childbearing potential . Fertile male , define male physiologically capable conceive offspring unless subject partner child bear potential agree comply acceptable contraception female partner lactate . Prior liver biopsy ( time past ) , indicate Stage 3 high fibrosis Ishak Metavir score system equivalent ( i.e . great moderate fibrosis ) . Any cause significant liver disease addition HCV , may include , limited , malignancy hepatic involvement , hepatitis B , drug alcohol relate cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , primary biliary cirrhosis . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Blood donation approximately 500 mL significant blood loss within 56 day prior dose . Any medical psychiatric condition laboratory abnormality , view Investigator , likely interfere study put subject risk . Concurrent participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hepatitis C Infection</keyword>
	<keyword>Treatment Naïve , Chronic</keyword>
	<keyword>First In Human</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Multiple Ascending Dose</keyword>
</DOC>